Edition:
United States

Viking Therapeutics Inc (VKTX.OQ)

VKTX.OQ on NASDAQ Stock Exchange Capital Market

3.96USD
15 Dec 2017
Change (% chg)

$0.22 (+5.88%)
Prev Close
$3.74
Open
$3.73
Day's High
$3.97
Day's Low
$3.70
Volume
235,972
Avg. Vol
156,262
52-wk High
$4.28
52-wk Low
$0.88

Select another date:

Tue, Dec 5 2017

BRIEF-Viking Therapeutics Announces Proposed Public Offering Of Common Stock

* VIKING THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Viking Therapeutics Announces Positive Top-Line Results From Phase 2 Study Of VK5211 In Patients Recovering From Hip Fracture

* VIKING THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2 STUDY OF VK5211 IN PATIENTS RECOVERING FROM HIP FRACTURE

BRIEF-Viking Therapeutics reports third quarter 2017 financial results

* Viking Therapeutics reports third quarter 2017 financial results and provides corporate update

BRIEF-Viking Therapeutics files for sale of up to 6.9 mln shares by selling stockholder

* Viking Therapeutics Inc files for sale of up to 6.9 million shares of co's common stock by selling stockholder Lincoln Park Capital Fund Llc‍‍​ - SEC filing Source text: (http://bit.ly/2x3eVPr) Further company coverage:

BRIEF-VIKING THERAPEUTICS ANNOUNCES TOP-LINE RESULTS FROM PROOF-OF-CONCEPT STUDY OF VK0214

* VIKING THERAPEUTICS ANNOUNCES TOP-LINE RESULTS FROM PROOF-OF-CONCEPT STUDY OF VK0214 IN IN VIVO MODEL OF X-LINKED ADRENOLEUKODYSTROPHY (X-ALD)

BRIEF-VIKING THERAPEUTICS ANNOUNCES PURCHASE AGREEMENTS FOR UP TO $16.25 MILLION WITH LINCOLN PARK CAPITAL

* VIKING THERAPEUTICS ANNOUNCES PURCHASE AGREEMENTS FOR UP TO $16.25 MILLION WITH LINCOLN PARK CAPITAL

BRIEF-Viking Therapeutics Q2 loss per share $0.21

* Viking Therapeutics reports second quarter 2017 financial results and provides corporate update

BRIEF-Viking Therapeutics completes enrollment in Phase 2 study of VK5211

* Viking Therapeutics completes enrollment in Phase 2 study of VK5211 in patients recovering from hip fracture

BRIEF-Viking therapeutics appoints Charles A. Rowland Jr. to board

* Viking Therapeutics appoints Charles A. Rowland Jr. to board of directors Source text for Eikon: Further company coverage:

Select another date: